Literature DB >> 31238738

Cause-specific death assessment of patients with stage I small-cell lung cancer: a competing risk analysis.

Jiaqing Liu1,2,3,4, Huaqiang Zhou1,2,3,4, Yaxiong Zhang1,2,3, Wenfeng Fang1,2,3, Yunpeng Yang1,2,3, Shaodong Hong1,2,3, Gang Chen1,2,3, Shen Zhao1,2,3, Xi Chen1,2,3, Zhonghan Zhang1,2,3, Wei Xian4, Jiayi Shen4, Yan Huang1,2,3, Hongyun Zhao1,2,3, Li Zhang1,2,3.   

Abstract

Aim: Stage I small-cell lung cancer (SCLC) is a potentially curable disease that needs timely and multidisciplinary management. The aim of this study was to evaluate the probability of cause-specific mortality for patients with stage I SCLC. Material & methods: We identified patients in the SEER database and constructed a proportional subdistribution hazard model to evaluate cancer-specific mortality. A nomogram was built based on Fine and Gray competing risk regression model.
Results:  A total of 864 stage I SCLC patients were identified. The 5-year cumulative incidence of SCLC-specific mortality was 56.2%, while that for other causes of death was 17.3%. The c-index for the prognostic prediction model was 0.66. Besides, the nomogram was well calibrated.
Conclusion: Our nomogram might serve as a reference for clinicians when evaluating the prognosis of stage I SCLC.

Entities:  

Keywords:  SCLC; SEER; cancer-specific death; competing risk nomogram

Year:  2019        PMID: 31238738     DOI: 10.2217/fon-2018-0888

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis.

Authors:  Jan A Stratmann; Radha Timalsina; Akin Atmaca; Vivian Rosery; Nikolaj Frost; Jürgen Alt; Cornelius F Waller; Niels Reinmuth; Gernot Rohde; Felix C Saalfeld; Aaron Becker von Rose; Fabian Acker; Lukas Aspacher; Miriam Möller; Martin Sebastian
Journal:  Ther Adv Med Oncol       Date:  2022-06-04       Impact factor: 5.485

2.  Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma.

Authors:  Xiaofeng Ni; Ding Li; Shengjie Dai; Hao Pan; Hongwei Sun; Jianyang Ao; Lei Chen; Hongru Kong
Journal:  Biomed Res Int       Date:  2021-03-29       Impact factor: 3.411

3.  Sites of Synchronous Distant Metastases, Prognosis, and Nomogram for Small Cell Lung Cancer Patients with Bone Metastasis: A Large Cohort Retrospective Study.

Authors:  Zhiyi Fan; Zhangheng Huang; Yuexin Tong; Zhe Zhu; Xiaohui Huang; He Sun
Journal:  J Oncol       Date:  2021-07-28       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.